KW 3902
KW 3902 structure
|
Common Name | KW 3902 | ||
|---|---|---|---|---|
| CAS Number | 136199-02-5 | Molecular Weight | 356.46200 | |
| Density | 1.262g/cm3 | Boiling Point | 578ºC at 760mmHg | |
| Molecular Formula | C20H28N4O2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 303.4ºC | |
|
The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects.
Am. J. Ther. 17(1) , 53-60, (2010) Rolofylline is a potent, selective adenosine A1 receptor antagonist that was under development for the treatment of patients with acute decompensated heart failure and renal function impairment. This was a phase I, randomized, open-label, 2-period, fixed-sequ... |
|
|
The disconnect between phase II and phase III trials of drugs for heart failure.
Nat. Rev. Cardiol. 10(2) , 85-97, (2013) Hospitalization for heart failure (HF) is a clinical entity associated with high postdischarge morbidity and mortality, yet few therapies are available to improve outcomes in patients with this condition. In the past decade, large phase III studies of HF trea... |
|
|
Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.
J. Card. Fail. 16(1) , 25-35, (2010) Current treatment for acute decompensated heart failure (ADHF) is associated with incomplete resolution of symptoms and signs, recurrent symptoms of heart failure in-hospital and after discharge and high mortality. Studies have consistently demonstrated an as... |
|
|
Adenosine A2 receptor activation attenuates afferent arteriolar autoregulation during adenosine receptor saturation in rats.
Hypertension 50(4) , 744-9, (2007) Adenosine is an important paracrine agent regulating renal hemodynamics via adenosine A1 and A2 receptors. To determine the interactions between adenosine A1 and A2 receptors and the possible role of adenosine as a modulator of afferent arteriolar autoregulat... |
|
|
Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function.
Eur. J. Heart Fail. 12(11) , 1238-46, (2010) The direct effects of adenosine A1 receptor antagonists on haemodynamic parameters in patients with acute heart failure (HF) remain largely unknown.We evaluated the haemodynamic effects of the AA(1)RA rolofylline in 59 HF patients with concomitant renal impai... |
|
|
Adenosine1 receptor antagonism: a new therapeutic approach for the treatment of decompensated heart failure.
Cardiol. Rev. 17(3) , 125-31, (2009) Heart failure (HF) remains a major cause of morbidity and mortality, even with the use of standard treatments in patients with chronic HF and acute decompensated HF. Impaired renal function is an important prognostic indicator for adverse clinical outcomes. E... |
|
|
Role of adenosine antagonism in the cardiorenal syndrome.
Cardiovasc. Ther. 26(4) , 276-86, (2008) Acute decompensated heart failure (ADHF), generally related to signs and symptoms of volume overload, is one the most common reasons for hospitalization in the United States. Recently, it has been observed that the majority of patients with ADHF have baseline... |
|
|
Combined effects of carbonic anhydrase inhibitor and adenosine A1 receptor antagonist on hemodynamic and tubular function in the kidney.
Kidney Blood Press. Res. 30(6) , 388-99, (2007) Carbonic anhydrase inhibitors (CAI) reduce proximal reabsorption, activating tubuloglomerular feedback (TGF) and reducing glomerular filtration rate (GFR). Adenosine A(1) receptors (A(1)R) mediate the TGF response and stimulate proximal reabsorption.Clearance... |
|
|
Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes.
Cardiology 115(1) , 29-36, (2010) To evaluate physician-determined worsening heart failure (PD-WHF) in patients admitted with acute heart failure (AHF).The PROTECT pilot study evaluated rolofylline, an adenosine A(1) receptor antagonist, versus placebo in patients with AHF and renal impairmen... |
|
|
The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study.
J. Card. Fail. 16(9) , 714-9, (2010) Worsening renal function (WRF) portends a poor prognosis, and recent deterioration in creatinine might identify patients with elevated intrarenal adenosine in whom adenosine A(1) antagonism may improve renal hemodynamics and function. The purpose of this pilo... |